O'Reilly Automotive Inc. Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? O'Reilly Automotive Inc. Common Stock trades at $87.78 (market cap $69.59B), while Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B). The key difference: O'Reilly Automotive Inc. Common Stock is far larger — about 6.6× Vaxcyte Inc. Common Stock's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, O'Reilly Automotive Inc. Common Stock nearer its low. Which is the better fit depends on your goals.
| ORLY | PCVX | |
|---|---|---|
Market Cap | $69.59B | $10.51B |
Volume | 3,367,517 | 2,644,694 |
Sector | Consumer Cyclical | Health |
52-Week High | $102.12 | $73.82 |
52-Week Low | $82.73 | $40.32 |
Enterprise Value | $78.92B | $9.14B |
Typical Hold Time | — | 0 Days |
Signals from Pluang's Aura AI — not financial advice
O'Reilly Automotive (ORLY) trades at $86.03, down 0.72% on the day, amid a mixed technical picture with a bullish overall signal but bearish moving averages. The company reported strong fundamentals with 2025 revenue of $17.78 billion and net income of $2.54 billion, maintaining a robust net income margin of 14.27%. Recent news highlights its defensive positioning in the auto parts market and upcoming Q3 2026 earnings release on October 28, 2026.
The outlook remains positive with a consensus price target of $106.09, implying significant upside. Key opportunities include resilient demand from an aging vehicle fleet and expansion plans in Mexico. Risks involve competitive pressures and potential macroeconomic headwinds affecting consumer spending on auto repairs. Analyst sentiment is strongly bullish with 59.57% buy ratings.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
O'Reilly Automotive sells automotive aftermarket parts, tools, supplies, equipment, and accessories. It serves both professional service providers and do-it-yourself customers through its store network.
Read more on ORLY →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →